Sign Up for a Free Account
  • Updated 02.28.2021
  • Released 12.15.1999
  • Expires For CME 02.28.2024

Chemotherapy-induced neuropathies

Introduction

Overview

Chemotherapy-induced toxicities, such as neuropathy, are accepted consequences of some effective therapies. However, neuropathy is also a primary dose-limiting complication of many compounds. Early recognition and management of symptoms have become crucial to any neurologist participating in the care of these complicated patients. Preventative strategies to limit neurotoxicity have been long sought but remain limited. The author details the well-known and emerging medications associated with chemotherapy-induced neuropathy, such as bortezomib, enfortumab vedotin, eribulin, brentuximab vedotin, ixabepilone, polatuzumab vedotin, and immune check point inhibitors.

Key points

• Chemotherapy-induced peripheral neuropathy is a dose-dependent complication of numerous agents.

• Some individuals have increased susceptibility to chemotherapy-induced peripheral neuropathy because of genetic differences or pre-existing neuropathy.

• New agents and modified existing agents associated with chemotherapy-induced peripheral neuropathy continue to emerge.

• Effective preventative strategies to reduce toxicity are limited.

Start a MedLink Neurology trial
to unlock 3 free articles.

  • Nearly 3,000 illustrations, 
including video clips of 
neurologic disorders.

  • Every article is reviewed by our esteemed Editorial Board for accuracy and currency.

  • Full spectrum of 
neurology in 1,200 
comprehensive articles.

Questions or Comment?

MedLink, LLC

10393 San Diego Mission Rd, Suite 120

San Diego, CA 92108-2134

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com